Clioquinol is an 8-hydroxyquinoline derivative that was widely used from the 1950s to 1970s as an oral antiparasitic agent. In 1970, the oral forms were withdrawn from the market due to reports of toxicity, but topical formulations for antifungal treatment remained available. Thus, the purpose of this study was to evaluate the toxicity, anti-Candida and antidermatophyte activity and to determine pharmacodynamic characteristics of clioquinol and other 8-hydroxyquinoline derivatives (8-hydroxy-5-quinolinesulfonic acid and 8-hydroxy-7-iodo-5-quinolinesulfonic acid). Antifungal activity was tested by broth microdilution and the fungicidal or fungistatic effect was checked by a time-kill assay. Permeation and histopathological evaluation were performed in Franz diffusion cells with ear skin of pigs and examined under light microscopy. An HET-CAM test was used to determine the potential irritancy. The three compounds were active against all isolates showing anti-Candida and antidermatophyte activity, with MIC ranges of 0.031-2 μg/ml, 1-512 μg/ml, and 2-1024 μg/ml for clioquinol, 8-hydroxy-5-quinolinesulfonic acid, and 8-hydroxy-7-iodo-5-quinolinesulfonic acid, respectively. All compounds showed fungistatic effect for Candida, 8-hydroxy-5-quinolinesulfonic acid, and 8-hydroxy-7-iodo-5-quinolinesulfonic acid showed a fungicidal effect for M. canis and T. mentagrophytes, and clioquinol showed a fungicidal effect only for T. mentagrophytes. Furthermore, they presented a fungicidal effect depending on the time and 
Introduction
Fungal infections represent a threat to human health. They can be classified according to the extent of infected tissue as: superficial, cutaneous, subcutaneous, and systemic mycoses. Such infections cause conditions that range from athlete's foot to severe disseminated disease. Dermatophytesmainly represented by the genera Trichophyton, Microsporum and Epidermophyton-are quite widespread worldwide and are naturally able to cause an infection in the healthy population. These fungi affect keratinized structures of the body and can cause chronic and uncontrolled infections. 1, 2 In contrast, mucosal infections are mostly caused by opportunistic yeasts, mainly species of Candida. These yeasts can develop infections especially when the immune system of the patient is compromised. Candida spp. have also been associated with systemic infections, and with high rates of morbidity and mortality. 2 In addition, the incidence and severity of fungal diseases has increased in recent years, and the widespread use of antifungal agents has serious implications for antifungal therapy due to the emergence of resistant strains leading to treatment failures. This scenario represents a public health problem. 3, 4 Besides problems related to resistance, many antifungal drugs have several limitations associated with toxicity. Safety profiles of the antifungals have limited their clinical use and have restricted the number of medicines available to treat such infections. 5 In view of this situation, there is a clear need for reevaluation of antifungals and introduction of new pharmaceutical strategies. In this context, 8-hydroxyquinoline derivatives may come to play an important role in antifungal therapy. Clioquinol (compound 1; 5-chloro-7-iodo-8-hydroxyquinoline) is a dihalogenated 8-hydroxyquinoline that was widely used from the 1950s to 1970s as an oral antiparasitic agent. 6 In 1970, the oral formulation compounds were withdrawn from the market due to reports of subacute myelo-optic neuropathy (SMON) in Japanese patients. 7 However, these reports are controversial because the clioquinol had been used for 20 years prior to these events without incident. Moreover, these effects could be associated with formulations used in Japan and/or with genetic susceptibility (inherited increase in the risk of developing a disease) 6, 7 since they were rarely observed in other countries. 8 Topical formulations for the treatment of fungal infections have remained available in many countries. 6 The use of topical clioquinol in high concentrations can cause skin irritation, but it is not a common contact allergen and has not been associated with development of skin malignancies. 9, 10 Furthermore, there are few reports of antimicrobial resistance against clioquinol. 10 Recently, compound 1 had a renewed interest as a lead compound in the design of anticancer agents and a chelating agent with the potential effect for the treatment of Alzheimer's, Parkinson's and Huntington's disease. [11] [12] [13] [14] There is already great potential for reintroduction of compound 1 for new indications, but its mode of action on fungal cells has not yet been elucidated. Researchers have already proposed other 8-hydroxyquinoline derivatives with antifungal potential but have used outdated methodologies and without toxicological information on human cells. 15, 16 Thus, the purpose of this study was to evaluate the toxicity, anti-Candida and antidermatophyte activity (n = 73) and to determine pharmacodynamic characteristics of clioquinol (compound 1) and two other 8-hydroxyquinoline derivatives: compound 2 (8-hydroxy-5-quinolinesulfonic acid) and compound 3 (8-hydroxy-7-iodo-5-quinolinesulfonic acid) in order to find novel antifungals and to gain some insights into their pharmacodynamic characteristics. Sulfonic acid derivatives have the advantage of being easily modified while clioquinol is less reactive. Thus, it is possible to obtain a great structural diversity using these compounds. Furthermore, they have fewer halogen atoms than compound 1, which can be considered an important and favorable structural characteristic to reduce the toxicity.
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Methods
Fungal strains
A total of 73 strains were included in this study: C. albicans (11) , C. glabrata (10) , C. krusei (9) , C. parapsilosis (11), C. tropicalis (11) , M. canis (6) , M. gypseum (5), T. mentagrophytes (5), and T. rubrum (5) . All strains were deposited in the Mycology Collection of Universidade Federal do Rio Grande do Sul (Porto Alegre, Brazil) and originated from the National Programme of Quality Control of Brazil: nail and skin scrapings, hemoculture, vaginal secretions, urine, tracheal aspirate, and catheter tip. Standard strains of C. albicans (ATCC 18804), C. krusei (ATCC 6258), C. parapsilosis (ATCC 22019) and C. tropicalis (ATCC 750) were obtained from ATCC (American Type Culture Collection, Manassas, VA, USA) and were included as controls.
Antifungal compounds
Clioquinol (compound 1; MW = 305.50 g/mol), 8-hydroxy-5-quinolinesulfonic acid (compound 2; MW = 225.22 g/mol) and 8-hydroxy-7-iodo-5-quinolinesulfonic acid (compound 3; MW = 351.12 g/mol) were purchased from Sigma-Aldrich (St. Louis, MO, USA). For the experiments, these compounds were dissolved in DMSO (Sigma-Aldrich) and after being diluted in RPMI 1640 (Gibco; Grand Island, NY, USA), buffered with MOPS (Sigma-Aldrich) to obtain a maximum concentration of 2% DMSO.
Antifungal susceptibility testing
Minimum inhibitory concentrations (MICs) of analogues of 8-hydroxyquinoline were determined by the broth microdilution method according to M27-A3 protocol for the Candida species and M38-A2 for the filamentous fungi (Microsporum spp. and Trichophyton spp.). 18, 19 • C on SDA (Sabouraud dextrose agar; HiMedia, Mumbai, India) with chloramphenicol and it was adjusted to a 0.5 McFarland turbidity standard (1-5 × 10 6 cfu/ml). A 1:10 dilution of this suspension was made by adding 1 ml of fungal suspension to 9 ml of RPMI 1640 with or without (growth control) the desired amount of antifungal compounds. This dilution resulted in a solution with an inoculum of approximately 1-5 × 10 5 cfu/ml. 21 For the filamentous fungi (M. canis MCA 01 and T. mentagrophytes TME 40), a suspension of each fungus was prepared from a 7-day culture at 30 • C on potato dextrose agar (HiMedia) and it was adjusted to 1-3 × 10 3 cfu/ml in RPMI 1640 with or without (control) the desired amount of antifungal compounds. 22 When used to assess an antimicrobial agent, kill curves were constructed by testing several multiples of the MIC. The concentrations used for each compound were: MIC, MIC×2, MIC×4, and MIC×8. All test solutions and controls were made in triplicate, and they were incubated at 35
• C (Candida) or 30
• C (dermatophytes). At predetermined time points (0, 3, 6, 12, 24, and 48 h for Candida and 0, 3, 6, 12, 24, 48, and 96 h for dermatophytes), 100-μl samples were aseptically removed from each tube and serially diluted 10-fold (until 10 −3 ) with sterile water.
Then, 15 μl directly from the test solution and each dilution solution were plated onto a SDA plate, using a Drigalski spreader. 22 Plates were incubated at 35
• C for 48 h for Candida and 30
• C for 96 h for dermatophytes. After this period, the colony count was performed. Time kill curves were constructed by plotting mean log 10 cfu/ml against the exposure time of fungal cells to various concentrations of the antifungal agents, including the standard deviations. A fungicidal effect was considered when there was a decrease of ≥99.9% in the log 10 of the number of cfu/ml compared with starting inoculum.
Determination of permeation and histopathological evaluation of 8-hydroxyquinoline derivatives
Tissue samples from adult male pigs, freshly slaughtered at the Institute Federal of Santa Catarina, Concordia campus, were used to evaluate the formation of tissue damage due to the action of compounds 1, 2, and 3. Pigs were slaughtered according to the rules of the Brazilian Ministry of Agriculture, respecting animal welfare. 23 Ear skin of pigs was used in this study. The tissues were removed within a period of 5 min after the slaughter; the hairs were carefully removed by an electric trimmer and transported to the laboratory in an ice-cold Krebs-Hepes buffer (INLAB, São Paulo, Brazil). Skin samples were mounted in Franz diffusion cells (Logan Instrument Corp., Somerset, NJ, USA) with the diffusion area of approximately 1.75 cm 2 . The epidermal side of the skin was exposed to a phosphate-buffered saline (PBS) pH 7.0 (negative control) and to 0.1 M NaOH solution (positive control) for a period of 6 h (time that the permeation profile is more intense). The 8-hydroxyquinoline derivatives were dissolved in a PBS pH 7.0 at a concentration of 1 mg/ml (a higher concentration than MIC). The epidermal side of the skin was subjected to extract contact with this solution for a period of 6 h. Fragments of these tissues were harvested, fixed in 10% neutral-buffered formalin, processed routinely and stained with hematoxylin and eosin, and examined under light microscopy. The experiments were carried out in triplicate.
Hens' egg test on the chorioallantoic membrane (HET-CAM)
White fertile eggs of fresh Lohmann commercial breed (Lohmann selected Leghorn, LSL, São José do Rio Preto, Brazil) were used in the HET-CAM test. The eggs were kept at optimized incubation conditions (temperature between 38 to 39
• C and humidity between 55 and 60% for 10 d). On the 10th day, the egg shell, around the airspace, was carefully removed with a rotary tool (Dremel, Racine, WI). Afterward, 0.3 ml of each compound at a concentration of 1 mg/ml was added to each egg, respectively (negative control-0.9% saline solution; positive control-0.1 M NaOH solution; test substances-compounds 1, 2, and 3). The irritation effect was evaluated at 30 s, 2 min, and 5 min after the application of each substance. The experiment was performed in triplicate. The result of the irritation score (IS) was given according to the equation below, on a scale from 0 to 4.9 denoting nonirritant (or practically no irritation) and 5.0 to 21 denoting irritant (moderate/severe or extreme irritation). 24 Comparison of IS was analyzed by one-way analysis of variance (ANOVA) and Tukey's multiple comparisons test. P ≤ .05 was considered statistically significant.
I S = (301 − Hemorr hage Ti me) 300 x5
Results
All 8-hydroxyquinoline derivatives were able to inhibit the in vitro growth of the tested Candida spp., Microsporum spp. and Trichophyton spp. The MIC values ranged from 0.031-2 μg/ml, 1-512 μg/ml, and 2-1024 μg/ml for compounds 1, compounds 2, and compounds 3, respectively; the cell damage at the MIC exceeded 90% for all isolates. The antifungal data for the three compounds against Candida spp. (n = 52) and dermatophytes (n = 21) are summarized in Table 1 . The results are expressed as ranges of variation of minimum and maximum MIC values obtained for each species as well as cell damage caused by each compound at its MIC (presented as average ± standard deviation). Also, the values of MIC 50 (MIC value that inhibits 50% of the isolates) and MIC 90 (MIC value that inhibits 90% of the isolates) were determined for each tested species. MIC values of the compounds against all isolates are available in the supplementary material (Table S1 and  Table S2 ).
Regarding the fungicidal kinetics, graphical representations of the log 10 of the numbers of CFU/ml versus time for different concentrations (MIC, MIC×2, MIC×4, and MIC×8) of compounds 1, 2, and 3 are presented in Figure 1 .
Compound 1 exhibited fungistatic (< 99.9% decrease in the log 10 of the number of cfu/ml compared with starting inoculum) activity against C. albicans and M. canis at all test concentrations. At concentrations ranging from MIC to MIC×4, slight growth was observed for C. albicans, but the growth was less than that observed with the control. For M. canis, the number of cfu/ml remained constant or with a small decrease over time, and the greatest reduction was perceptible in MICx8 within 48 h. In contrast, compound 1 exhibited fungicidal (≥99.9% decrease in the log 10 of the number of cfu/ml compared with starting inoculum) activity for the T. mentagrophytes isolate. However, this effect was concentration and time dependent. For this isolate, all test concentrations showed a fungicidal effect when evaluated at 96 h, and the MIC×8 had the same effect in less time-48 h. In none of the test concentrations was there an increase in the number of cfu/ml, independent of time.
Compound 2 showed a similar inhibition profile to compound 1 for C. albicans, presenting a fungistatic effect in all test concentrations. However, growth of the C. albicans strain was also observed at MIC×8 within 6 h. After this time, at this concentration, a stabilization or slight decline in growth was observed. This exhibited a fungicidal effect for the two dermatophyte strains. Although the fungicidal activity varied among test isolates, it was observed that fungicidal capacity increased with increasing concentrations of compound 2 and exposure time to this compound. For M. canis, the number of CFU/ml remained constant or with a small decrease in MIC. At the concentrations equal to MIC×2 and MIC×4, a fungicidal effect was observed at 96 h. At MIC×8, this effect was observed at 24 h, and it remained so until 96 h. Regarding T. mentagrophytes, the fungicidal effect was only seen at 96 h for MIC×4 and MIC×8.
As with the other two compounds, compound 3 exhibited fungistatic activity for C. albicans. On the other hand, when analyzing the results of this compound, a different effect was observed. Until 24 h, a better inhibitory effect was observed at the MIC followed by MIC×2, MIC×4 and MIC×8, respectively. At 48 h, a better inhibitory effect was seen in MIC×2 followed by MIC×4, MIC and MIC×8. In general, at all concentrations, cell growth was observed, but growth was less than in the control. This effect was not observed for the filamentous fungi tested in this study. At the concentrations equal to MIC and MIC×2, a slight decrease in the number of cfu/ml was noted for M. canis and T. mentagrophytes. MIC×4 demonstrated fungicidal activity in 96 h for both dermatophytes; and MIC×8 was fungicidal at 24 h and 12 h for M. canis and T. mentagrophytes, respectively.
The histopathological evaluation by microscopic analysis of the ear skin incubated with compounds 1, 2, and 3 showed no lesions (Fig. 2) , demonstrating a low topical toxicity of the compounds. This allowed continuing the permeation studies in order to determine the site of accumulation of the compounds that showed a different profile. Compound 3 accumulated on the receptor compartment of the Franz cell, suggesting that there is permeation through the skin and muscle, while compounds 1 and 2 were 
Discussion
Susceptibility tests with 8-hydroxyquinoline derivatives were carried out with a variety of yeasts and filamentous fungi. Currently, among the major drugs used in the treatment of Candida spp. are azoles, echinocandins and amphotericin B. 25 Antifungals usually used were not effective in inhibiting some of these isolates in vitro. A total of 21 of the 52 Candida isolates were resistant or showed a lower susceptibility to more than one antifungal azole. 26 Furthermore, the CG 40039, CK 01, and CK 02 isolates presented resistance or showed a lower susceptibility to at least one azole antifungal and to anidulafungin. Terbinafine and griseofulvin are among the drugs commonly used for dermatophytosis treatment, 27 and it was observed that among the 21 dermatophytes evaluated, five of them (MCA 36, MCA 40, MGY 58, TME16, and TME 34) showed a lower susceptibility to these two drugs and to ketoconazole as well. Microbiological resistance is a determining factor for the occurrence of success or failure in therapy, and in vitro tests are important for assessment. 4 The three 8-hydroxyquinoline derivatives showed in vitro activity for all isolates tested. These findings are very important, since some of these isolates have multiresistance to drugs used in therapy.
The mode of action of clioquinol and other 8-hydroxyquinoline derivatives on the fungal cells is not well understood. It is known that the group of 8-hydroxyquinoline derivatives inhibits certain enzymes related to DNA replication in viruses and 8-hydroxyquinoline inhibits RNA synthesis in yeast. However, studies on the mechanism of action of this group are scarce. Still, it is important to highlight that modifications in the molecule structure may provide additional mechanisms. 29, 30 The performance of the three compounds against dermatophytes indicated greater efficacy for compound 1, followed by compound 2 and compound 3. This same order of effectiveness of the compounds was also observed against yeasts. Compound 1 remained the most active and MIC values of all tested compounds were lower for Candida spp. than dermatophytes.
The literature has shown that the biological activity depends on the nature of the groups attached to the 5-and 7-positions of quinoline ring. Previous studies demonstrated that the presence of chlorine and bromine halogens in the 5-or 7-positions of substances, generally, was related to an increased antifungal activity, which was not observed with the fluorinated compounds. The presence of iodine in 7-position has also led to an improvement in the activity against some species. 16 This evidence corroborates the results found by our group, in which compound 1 (clioquinol) was the most active molecule. This finding may be related to the presence of iodine in the 7-position and chlorine in 5-position of its structure. 16 Although it was verified that the presence of halogens may be linked to the relevant activity observed, it is known that they can influence the increase in toxicity of compounds. Compound 2 presented antifungal activity even without the presence of halogen in its structure. The MIC values were similar or slightly lower than the values of compound 3. Gershon et al. evaluated a series of 8-hydroxyquinoline derivatives (including compounds 2 and 3) containing a sulfonic acid against six fungal species: Aspergillus niger, A. oryzae, Myrothecium verrucaria, Trichoderma viride, Mucor circinelloides and T. mentagrophytes. 16 In contrast to results found in our study, these researchers found no antifungal activity for compound 2 against the species tested; however, tests with yeasts were not performed, and M. canis, M. gypseum, and T. rubrum were also not evaluated. Moreover, 100 μg/ml was the highest tested concentration of the compound and, as we have shown in this study, filamentous fungi were less susceptible. The advantage of compound 2 in relation to other 8-hydroxyquinoline derivatives tested is the absence of a halogenated substituent, which could decrease the toxicity of the molecule. Furthermore, the modification of the 8-hydroxyquinoline with sulfonic acids improves the water solubility, since this is a polar group, and this property is important for drugs. 31 Antifungal activity of the 8-hydroxyquinoline derivatives against different genera was confirmed by a timekill assay that is concentration and/or time dependent. 32 Compound 1 is a known antifungal and the literature describes the 8-hydroxyquinoline derivatives as fungistatic agents. 33, 34 However, we were unable to find consistent information in the literature with appropriate methodologies demonstrating this effect. Although compound 1 has been used for many years, studies about the time-kill have not yet been performed. Therefore, it is extremely important to make a better assessment of the subject in order to have a greater pharmacodynamic understanding of the 8-hydroxyquinoline derivatives. In fact, our results showed a fungistatic effect for C. albicans and M. canis. A reduction greater than 50% of CFU/ml compared to the C. albicans starting inoculum was achieved in just 12 h at a concentration equal to MIC×8. For M. canis, this reduction was achieved in 24 h at MIC×8 and in 48 h at MIC×4. However, contrary to the literature reports, 33, 34 this compound was fungicidal for T. mentagrophytes. All tested concentrations had 100% reduction of cfu/ml in 96 h. The timekill assays for filamentous fungi were evaluated until the maximum time of 48 h. 22, 35 We opted to evaluate at 96 h because it is the incubation time in susceptibility tests.
19 Surprisingly, this time gave us the best result for T. mentagrophytes. In addition, at MIC×8, with only 6 h of contact, there was already >50% reduction of cfu/ml and also for 12 h at MIC×4. At 24 h, all concentrations reached >50% reduction of cfu/ml compared to the starting inoculum for this fungus. The fungicidal effect of compounds 2 and 3 has not yet been reported. With regard to dermatophytes, an exposure time of 96 h was also important for the effect of these two compounds. In 96 h, they had a fungicidal effect for dermatophytes at the highest concentrations and reduction >50% in cfu/ml compared to the initial inoculum for the lowest concentrations. Since the time-kill assay showed that the fungi are not immediately killed (Fig. 1) , the exposure time can play a significant role in the fungicidal action of these compounds.
Compound 2 had a fungistatic effect for C. albicans and the maximum reduction in cfu/ml compared to the initial inoculum was achieved immediately after exposure, reaching from 33.33% to 42.86% reduction, depending on the compound concentration.
The fungistatic effect for C. albicans was also observed for compound 3. Additionally, a paradoxical effect seems to be involved. We postulate that C. albicans showed higher growth in elevated concentrations (MIC×8 and MIC×4) when compared to the MIC; and the concentrations equal to MIC and MIC×2, immediately after exposure, were able to reduce more than 50% of cfu/ml. However, the paradoxical growth phenomenon is still only a supposition since it is necessary to test more isolates to confirm this effect. Some authors have already reported this effect with echinocandin. Some yeasts and filamentous fungi are able to grow in elevated caspofungin concentrations much higher than the MICs. 36 This phenomenon can be associated with the metabolic adaptation of microorganisms and activation of resistance mechanisms, or it can be related to aggregation of the drug at high concentrations. 2, 37 However, the abilities of subpopulations to survive at high drug concentrations may be only an in vitro effect. Moreover, current data suggest that the clinical relevance of the paradoxical growth effect is not likely to be significant. 37 It was noted that none of the compounds showed fungicidal activity on C. albicans, although the MIC values observed in broth microdilution tests were lower than for dermatophytes. The differences between the forms of preparation of fungal inoculum for the time-kill assay may have contributed to this. For dermatophytes, the starting inoculum used for time-kill tests was similar to that recommended for in vitro susceptibility determinations, approximately 1-3 × 10 3 cfu/ml. 22 Using the same starting inoculum facilitates comparisons between MIC and time-kill data by precluding potential discrepancies resulting from an inoculum effect. The inoculum of yeasts for the time-kill requires certain changes due to the limit of quantitation. The starting inoculum recommended for in vitro antifungal susceptibility testing (0.5-2.5 × 10 3 cfu /ml) 18 for Candida spp. is much lower than the inoculum recommendations for time-kill testing (1-5 × 10 5 cfu/ml) for the same species. 21 Clinically, pharmacodynamic differences may influence the selection of optimal dose regimens for antifungal therapies. Although numerous factors may influence the in vivo activity of an agent, our data suggest that antidermatophyte activity of compounds 2 and 3 can be maximized by administering high doses. Agents in which the antifungal activity improves with increasing concentration (e.g., amphotericin B) may be optimized by the administration of prolonged therapeutic regimens. In contrast, the efficacy of tested compounds against Candida spp. does not improve with increasing concentration. This occurs because their fungistatic effects are concentration-independent. Fluconazole, one of the most used antifungals, acts in this way, requiring continuous administration of the drug. 38 Fungicidal results for dermatophytes were a stimulus to investigate the ex vivo toxic effects of 8-hydroxyquinoline derivatives. The low toxicity in histopathological evaluation and the low level of irritability presented by compounds are interesting properties for the development of new drugs for the treatment of dermatophytosis. Besides these features, the compounds should also have low skin permeability because dermatophytes only reach the level of the epidermis and the action of antifungals should be local. The accumulation of compounds 1 and 2 in epithelial tissue shows that they could have local action and also shows the possibility of their use in this type of infection. Compound 3 showed a high degree of permeation suggesting a systemic action.
When used topically, clioquinol can produce skin irritation, pruritis, erythema, swelling, or pain. 39 However, clioquinol is a rare sensitizer and has not been associated with the development of skin malignancies. 10 Lazarov found that only three of 2,156 patients in a contact dermatitis clinic were patch test positive to clioquinol 5%. 40 Similarly, Morris et al. found eight of 1,119 patients; 41 and Agner and
Menné reported that 21 of 4,556 patients were patch test positive to clioquinol. 42 Katsarou et al. reported cases of both type I and type IV hypersensitivities to topical clioquinol. Of the 664 patients studied with suspected contact dermatitis, 13 had an immediate patch test reaction (wheal and flare) to clioquinol, while six had a delayed patch test reaction. 43 Despite clioquinol being a slight sensitizer, modification of the chemical structure can result in cytotoxic activity. Thus, it is important to carry out toxicological studies using models such as HET-CAM, which allow to discriminate various levels of toxicity by means of the IS calculation. The HET-CAM is a very sensitive test to determine the irritation effect associated with topical use. In this way, this methodology becomes an alternative to other in vivo tests. 24, 44, 45 The sulfonic acid derivatives showed an appropriate score confirming their potential. Finally, 8-hydroxyquinoline derivatives showed antifungal activity of in vitro susceptibility testing. These compounds showed a fungicidal effect depending on the species, time and concentration. Compound 2 had an intermediate activity without permeating the skin. Moreover, it was nonirritant and did not possess dermatologic toxicity. Although this compound presents a high MIC, it is easily modified using classical reactions. Thus, it is possible to obtain a great structural diversity using this compound for antifungal drug design. Fungal susceptibility and toxicity against human cells could be optimized by appropriate structural modifications, providing selective antifungal agents that can become effective alternatives for the treatment of infections caused by resistant pathogens. However, more studies on pharmacokinetics, mechanism of action, and verification of in vivo toxicity are needed. Work in this direction is underway and the results will be reported in due course.
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